Selecta Biosciences, Inc. is a clinical-stage biotechnology company developing novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) platform creates a novel paradigm in immunotherapeutics and vaccines, enabling completely new applications while offering the potential of improved efficacy and safety profiles.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/15/14 | $20,000,000 |
Eminent Venture Capital Flagship Ventures I2BF Global Ventures Leukon Investments NanoDimension OrbiMed Advisors Polaris Partners RUSNANO | undisclosed | |
| 09/08/15 | $38,000,000 | Series E |
AJU IB Investment Eminent Venture Capital Flagship Ventures I2BF Global Ventures Leukon Investments NanoDimension OrbiMed Advisors Osage University Partners Polaris Partners Ridgeback Capital Management Sanofi-Genzyme BioVentures Sphera Global Healthcare | undisclosed |
